The Enticing Path of miR Therapeutics: Difficult but Not Without Prospects

MicroRNAs (miRs), short non-coding RNAs that regulate gene expression, are involved in various diseases like stroke, cancer, and androgenic alopecia. Specific miRs such as miR-511, miR-27-3p, and miR-214 have potential as biomarkers. Despite challenges like ubiquitous expression, non-specificity, and delivery issues in developing miR therapeutics, the article suggests that identifying significant miRs in diseases, developing miR-inhibitors with higher specificity, and using plant-derived miRs are promising opportunities. As of the article's publication, only 20 miR-therapeutics have entered clinical trials, with none reaching phase III trials.